Hernandez 2018 — Harmony Outcomes Albiglutide CVOT

The Lancet·October 27, 2018

Adrian F. Hernandez, et al.

Summary

Albiglutide was superior to placebo for major adverse cardiovascular events in patients with type 2 diabetes and cardiovascular disease.

Study Details

Study Design

Double-blind randomized placebo-controlled cardiovascular outcomes trial

Indication

Type 2 diabetes and cardiovascular disease

Intervention

Once-weekly albiglutide vs placebo

Species

Human

Sample Size

9,463 subjects

Risk of Bias Assessment

Sponsor-funded CVOT; drug later commercially discontinued